AMPH Amphastar Pharmaceuticals Inc

Price (delayed)

$41.665

Market cap

$2.04B

P/E Ratio

13.02

Dividend/share

N/A

EPS

$3.2

Enterprise value

$2.46B

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active ...

Highlights
The stock's P/E is 85% less than its 5-year quarterly average of 88.5 and 35% less than its last 4 quarters average of 19.8
The EPS has soared by 68% YoY and by 12% from the previous quarter
Amphastar Pharmaceuticals's quick ratio has decreased by 40% YoY

Key stats

What are the main financial stats of AMPH
Market
Shares outstanding
48.9M
Market cap
$2.04B
Enterprise value
$2.46B
Valuations
Price to book (P/B)
2.98
Price to sales (P/S)
2.97
EV/EBIT
11.23
EV/EBITDA
9.9
EV/Sales
3.64
Earnings
Revenue
$676.21M
EBIT
$219.27M
EBITDA
$248.86M
Free cash flow
$160.93M
Per share
EPS
$3.2
Free cash flow per share
$3.34
Book value per share
$13.98
Revenue per share
$14.03
TBVPS
$20.06
Balance sheet
Total assets
$1.57B
Total liabilities
$901.96M
Debt
$627.12M
Equity
$672.36M
Working capital
$299.91M
Liquidity
Debt to equity
0.93
Current ratio
2.18
Quick ratio
1.69
Net debt/EBITDA
1.71
Margins
EBITDA margin
36.8%
Gross margin
54.3%
Net margin
22.9%
Operating margin
31.3%
Efficiency
Return on assets
10.3%
Return on equity
24.8%
Return on invested capital
20.7%
Return on capital employed
16.6%
Return on sales
32.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMPH stock price

How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
1.15%
1 week
4.82%
1 month
2.67%
1 year
-32.42%
YTD
-32.64%
QTD
4.16%

Financial performance

How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$676.21M
Gross profit
$367.38M
Operating income
$211.56M
Net income
$154.69M
Gross margin
54.3%
Net margin
22.9%
The operating income has surged by 77% year-on-year and by 7% since the previous quarter
The net income has soared by 66% YoY and by 12% from the previous quarter
The company's gross profit rose by 38% YoY and by 4.6% QoQ
AMPH's operating margin is up by 36% year-on-year and by 2.3% since the previous quarter

Growth

What is Amphastar Pharmaceuticals's growth rate over time

Valuation

What is Amphastar Pharmaceuticals stock price valuation
P/E
13.02
P/B
2.98
P/S
2.97
EV/EBIT
11.23
EV/EBITDA
9.9
EV/Sales
3.64
The stock's P/E is 85% less than its 5-year quarterly average of 88.5 and 35% less than its last 4 quarters average of 19.8
The EPS has soared by 68% YoY and by 12% from the previous quarter
The price to book (P/B) is 28% lower than the last 4 quarters average of 4.1
Amphastar Pharmaceuticals's equity has increased by 23% YoY and by 5% from the previous quarter
Amphastar Pharmaceuticals's revenue has increased by 30% YoY and by 4.9% QoQ
AMPH's price to sales (P/S) is 30% less than its last 4 quarters average of 4.2 and 5% less than its 5-year quarterly average of 3.1

Efficiency

How efficient is Amphastar Pharmaceuticals business performance
The ROE has grown by 39% YoY and by 7% from the previous quarter
The ROS has grown by 38% YoY and by 6% from the previous quarter
The company's return on assets fell by 18% YoY and by 2.8% QoQ
The ROIC is down by 8% year-on-year and by 3.7% since the previous quarter

Dividends

What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMPH.

Financial health

How did Amphastar Pharmaceuticals financials performed over time
The total assets is 75% greater than the total liabilities
The total assets has surged by 103% year-on-year and by 4.1% since the previous quarter
Amphastar Pharmaceuticals's current ratio has decreased by 44% YoY
AMPH's debt is 7% smaller than its equity
Amphastar Pharmaceuticals's equity has increased by 23% YoY and by 5% from the previous quarter
Amphastar Pharmaceuticals's debt to equity has decreased by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.